Literature DB >> 19217279

Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?

Donald Maxwell Parkin1.   

Abstract

There has been a substantial decline in the use of female sex hormone replacement therapy (HRT) in the United Kingdom, particularly by post-menopausal women, since around 2000-2001. Given what is known of the risk of breast cancer in women receiving HRT, the decline in use should have resulted in a decrease in risk, and incidence rates about 14% lower than expected were predicted for the age group 50-59 in 2005. There has been a recent slowing and reversal of the increasing trends in incidence of breast cancer in the age group 45-64. This is most marked at ages 50-59, where rates since 1999 have been decreasing at 0.8% a year, following a long period of sustained increase. It seems probable that these two events are causally related.

Entities:  

Mesh:

Year:  2009        PMID: 19217279     DOI: 10.1016/j.ejca.2009.01.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  How to judge the association of postmenopausal hormone therapy and the risk of breast cancer.

Authors:  Ling Xu
Journal:  Front Med China       Date:  2010-08-05

2.  Breast Cancer and Socioeconomic Status in Austria.

Authors:  Ursula Kunze; Gabriela Böhm
Journal:  Breast Care (Basel)       Date:  2009-08-20       Impact factor: 2.860

3.  Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer.

Authors:  Montserrat Garcia-Closas; Necdet Burak Gunsoy; Nilanjan Chatterjee
Journal:  J Natl Cancer Inst       Date:  2014-11-12       Impact factor: 13.506

4.  Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models.

Authors:  J Ribes; L Esteban; R Clèries; J Galceran; R Marcos-Gragera; R Gispert; A Ameijide; M L Vilardell; J Borras; A Puigdefabregas; M Buxó; A Freitas; A Izquierdo; J M Borras
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

5.  Decline in US breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

6.  Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.

Authors:  C Pérez Piñero; A Bruzzone; M G Sarappa; L F Castillo; I A Lüthy
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 7.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

8.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.

Authors:  Ghada N Farhat; Rod Walker; Diana S M Buist; Tracy Onega; Karla Kerlikowske
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

9.  Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program.

Authors:  Yong Sik Jung; Kuk Young Na; Ku Sang Kim; Sei-Hyun Ahn; Soo Jung Lee; Soo-Joong Lee; Heung Kyu Park; Young Up Cho
Journal:  J Breast Cancer       Date:  2011-09-29       Impact factor: 3.588

10.  Cancer incidence in the United Kingdom: projections to the year 2030.

Authors:  M Mistry; D M Parkin; A S Ahmad; P Sasieni
Journal:  Br J Cancer       Date:  2011-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.